Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von Vortex 

Agios Pharmaceuticals Inc. diskutieren

Agios Pharmaceuticals Inc.

WKN: A1W2RM / Symbol: AGIO / Name: Agios / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /

21,00 €
-2,80 %

Einschätzung Buy
Rendite (%) -37,87 %
Kursziel 43,63
Veränderung
Endet am 22.07.26

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its price target lowered by analysts at Bank of America Corporation from $52.00 to $51.00. They now have a "buy" rating on the stock.
Ratings data for AGIO provided by MarketBeat

Einschätzung Buy
Rendite (%) -31,37 %
Kursziel 48,02
Veränderung
Endet am 04.09.26

Agios Pharmaceuticals (NASDAQ:AGIO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $56.00 price target on the stock.
Ratings data for AGIO provided by MarketBeat

Einschätzung Buy
Rendite (%) 5,00 %
Kursziel 41,65
Veränderung
Endet am 20.11.26

Agios Pharmaceuticals (NASDAQ:AGIO) had its price target lowered by analysts at HC Wainwright from $56.00 to $48.00. They now have a "buy" rating on the stock.
Ratings data for AGIO provided by MarketBeat

Einschätzung Buy
Rendite (%) 5,00 %
Kursziel 27,77
Veränderung
Endet am 20.11.26

Agios Pharmaceuticals (NASDAQ:AGIO) had its price target lowered by analysts at Bank of America Corporation from $54.00 to $32.00. They now have a "buy" rating on the stock.
Ratings data for AGIO provided by MarketBeat

Agios Pharmaceuticals (NASDAQ:AGIO) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Ratings data for AGIO provided by MarketBeat

Agios Pharmaceuticals (NASDAQ:AGIO) is now covered by analysts at Citigroup Inc.. They set a "buy" rating on the stock.
Ratings data for AGIO provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 28,80
Veränderung
Endet am 24.12.26

Agios Pharmaceuticals (NASDAQ:AGIO) had its price target raised by analysts at Bank of America Corporation from $32.00 to $34.00. They now have a "buy" rating on the stock.
Ratings data for AGIO provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 32,19
Veränderung
Endet am 24.12.26

Agios Pharmaceuticals (NASDAQ:AGIO) had its price target raised by analysts at Truist Financial Corporation from $32.00 to $38.00. They now have a "buy" rating on the stock.
Ratings data for AGIO provided by MarketBeat

Agios Pharmaceuticals (NASDAQ:AGIO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Ratings data for AGIO provided by MarketBeat